Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Mymetics Corporation (PK) | MYMXD | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.2605 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 0.10 - 0.2605 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 0.2605 | USD |
Mymetics Corporation (PK) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 79.13M | 303.76M | 80.39M | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Mymetics (PK) News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MYMXD Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.26 | 0.2605 | 0.10 | 0.1598287 | 476 | 0.0005 | 0.19% |
1 Year | 0.26 | 0.2605 | 0.10 | 0.1598287 | 476 | 0.0005 | 0.19% |
3 Years | 0.26 | 0.2605 | 0.10 | 0.1598287 | 476 | 0.0005 | 0.19% |
5 Years | 0.26 | 0.2605 | 0.10 | 0.1598287 | 476 | 0.0005 | 0.19% |
Mymetics (PK) Description
Mymetics Corporation is US registered biotechnology company with its main offices in Switzerland and the Netherlands. Focused on developing next generation vaccines for infectious and life threatening diseases. Mymetics core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins in combination with rationally designed antigens and membrane proteins. Mymetics currently has the following vaccines in its pipeline: HIV/AIDS and Covid-19 and collaboration projects in the cancer immunotherapy field. |